Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
By D. Harrison, R. Strong, Z. D. Sharp, James F. Nelson, C. M. Astle, K. Flurkey, N. Nadon, J. Wilkinson, K. Frenkel, C. Carter and 4 more. Nature, 2009
3,717 citations recorded by the source corpus.
Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies; however, whether inhibition of mTOR signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of ageing, or both. To our knowledge, these are the first results to demonstrate a role for mTOR signalling in the regulation of mammalian lifespan, as well as pharmacological extension of lifespan in both genders. These findings have implications for further development of interventions targeting mTOR for the treatment and prevention of age-related diseases.
Subfields: Aging, Endocrine and Autonomic Systems
View Paper: https://www.semanticscholar.org/paper/18013a95239d3fc4a9055f1c0d0fe6dd3e85b128
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Aging
- David M. Sabatini
- Mark P. Mattson
- Linda Partridge
- V. Longo
- Guido Kroemer
- Manuel Serrano
- Jesús Gil
- J. Kirkland
In Endocrine and Autonomic Systems
- David Raubenheimer
- Mark P. Mattson
- Stephen J. Simpson
- Linda Partridge
- E. Verdin
- John C. Newman
- V. Longo
- David M. Sabatini
Citations in the corpus
- Cellular Senescence: A Translational Perspective (2017, background): “…impairment, and immune dysfunction in mouse models, and enhance antibody response to influenza vaccination in elderly humans, among other effects (Harrison et al., 2009; Li et al., 2014; Majumder et al., 2012; Wilkinson et al., 2012, Zhang et al., 2014, Mannick et al., 2014; Bitto et al., 2016).”
- Metformin as a Tool to Target Aging (2016, positive): “When rapamycin is administered late in life, it extends lifespan (Harrison et al., 2009; Miller et al., 2011), slows aging in a dose-dependent manner, shows differential effects by sex (Wilkinson et al., 2012), and is synergistic with metformin.”
- Metabolic Plasticity in Stem Cell Homeostasis and Differentiation (2012, neutral): “Such mitochondrial infrastructure is also characteristic of hematopoietic stem cells (HSCs) (Piccoli et al., 2005) and mesenchymal stem cells (MSCs) (Chen et al., 2008b; Lonergan et al., 2006), Cell Stem Cell 11, November 2, 2012 ª2012 Elsevier Inc. 597 Catabolic and anabolic pathways are interconne”
- Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. (2011, methodology): “Our previous report (2) showed significant increases in longevity in male and female mice exposed to rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) protein kinase, from 20 months of age (Cohort 2005).”
- mTOR Signaling in Growth, Metabolism, and Disease. (2017, background): “Consistent with this, the mTOR inhibitor rapamycin is currently the only pharmacological treatment proven to extend life span in all of these model organisms (Bjedov et al., 2010; Harrison et al., 2009; Powers et al., 2006; Robida-Stubbs et al., 2012).”
- Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress (2010, background): “The degree that suppression of mTORC1 contributes to the increased life span of IGF-1R heterozygous mice is not known, but it is interesting to note that rapamycin treatment of mice also increased life span (Harrison et al., 2009).”
- Anti-apoptosis and cell survival: a review. (2011, background): “ability to prevent aging mediated necrosis suggests that autophagy may be capable of protecting from extreme stress [235,365,366].”
- Fat Tissue, Aging, and Cellular Senescence (2010, background): “…visceral to subcu- taneous fat, and most likely reduced fat cell progenitor turnover (Berryman et al., 2008)]; (iv) with rapamycin treatment [which limits fat tissue development (Chang et al., 2009; Harrison et al., 2009)]; and (v) after surgical removal of visceral fat (Muz- umdar et al., 2008).”
- Mechanistic Pathways of Sex Differences in Cardiovascular Disease. (2017, background): “Consistent with the genetic deletion of Rps6kb1, pharmacological intervention with rapamycin has most prominent effects in female mice (147).”
- Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease (2010, methodology): “we fed a rapamycin-supplemented diet identical to the diet that extended lifespan in mice[5] or control chow to groups of PDAPP”
- A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance and healthspan (2015, background): “Reduced signaling of the growth hormone/IGF-1 axis extends health- and lifespan in rodents (Brown-Borg, 2009; Guarente and Kenyon, 2000; Harrison et al., 2009; Junnila et al., 2013; Wullschleger et al., 2006).”